stoxline Quote Chart Rank Option Currency Glossary
iBio, Inc. (IBIO)
2.55  0.085 (3.45%)    06-12 15:55
Open: 2.5
High: 2.68
Volume: 217,352
Pre. Close: 2.465
Low: 2.48
Market Cap: 22(M)
Technical analysis
2024-06-12 4:22:48 PM
Short term     
Mid term     
Targets 6-month :  3.13 1-year :  3.65
Resists First :  2.68 Second :  3.13
Pivot price 2.38
Supports First :  2.12 Second :  1.78
MAs MA(5) :  2.45 MA(20) :  2.29
MA(100) :  1.71 MA(250) :  4.6
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  69.5 D(3) :  68.6
RSI RSI(14): 63.4
52-week High :  16 Low :  1.01
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ IBIO ] has closed below upper band by 12.7%. Bollinger Bands are 52% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.68 - 2.7 2.7 - 2.71
Low: 2.45 - 2.46 2.46 - 2.48
Close: 2.53 - 2.55 2.55 - 2.57
Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Headline News

Mon, 10 Jun 2024
iBio Inc. stock falls Monday, underperforms market - MarketWatch

Fri, 07 Jun 2024
iBio Inc. stock falls Friday, underperforms market - MarketWatch

Thu, 06 Jun 2024
iBio Inc. stock falls Thursday, underperforms market - MarketWatch

Wed, 05 Jun 2024
iBio Inc. stock falls Wednesday, underperforms market - MarketWatch

Mon, 03 Jun 2024
iBio, Inc. Updates Corporate Presentation with Future Outlook - - TipRanks

Mon, 03 Jun 2024
iBio Closes Sale of Manufacturing Facility in Texas - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 2 (M)
Held by Insiders 1.4e+006 (%)
Held by Institutions 0.7 (%)
Shares Short 20 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.563e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -10 %
Return on Assets (ttm) 206 %
Return on Equity (ttm) -26.9 %
Qtrly Rev. Growth 50000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -35 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -22 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.89
Stock Dividends
Dividend 0
Forward Dividend 90540
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android